Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_58099f3335eba674158774c1aa7745d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84d3fe7dc6459c64519c27abf0d5fe11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dde37eb4cf5a0ec16edb15edea87c472 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5512fb95759753d503bfd7fd53a9fe30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e636d32dfc0064b4beae0f5c26407c3e |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2278 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 |
filingDate |
2010-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2015-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_726d75952bb831836bd274567cc95c4d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85968fdade18ed7873c8479d0f3c837e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83f499635657ab3f9e02f9e5c58b0dd2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a80f7a346b1fa33a0c3edffddf3b1f0 |
publicationDate |
2015-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-9078866-B2 |
titleOfInvention |
Method for treating hyperglycemia with GLP-1 |
abstract |
A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with Type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015231067-A1 |
priorityDate |
2003-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |